[Discussion] can we stop arguing about receptor until somebody posts a number

Slightly embarrassed to be asking this, but: can we stop arguing about receptor until somebody posts a number.

Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.

GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.

Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.

Corrections welcome, especially the pedantic ones. Pedantry is how this board earns its reputation.